Chugai Pharmaceutical
Clinical trials sponsored by Chugai Pharmaceutical, explained in plain language.
A Japanese pharmaceutical company focused on biotech and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets immune overdrive in six rare diseases Results expected Mar 2027 (estimated)
- New hope for celiac sufferers: drug targets gut damage despite strict diet Results expected Jun 2027 (estimated)
-
New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for celiac sufferers: drug targets gut damage despite strict diet
Disease control Recruiting nowThis study tests an experimental drug called DONQ52 in people with active celiac disease who still have gut damage and symptoms even after following a gluten-free diet for at least a year. About 92 adults will receive either the drug or a placebo to see if it can heal the small i…
Phase 2 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug called ROSE12 help fight advanced solid tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial of AUBE00 begins
Disease control Recruiting nowThis early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for tough lung cancer: ALPS12 drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will ta…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC